Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Denali Therapeutics Inc
(NQ:
DNLI
)
64.66
USD
UNCHANGED
Streaming Delayed Price
Updated: 7:57 PM EST, Mar 1, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
65.50 (5)
Ask (Size)
68.00 (2)
Prev. Close
64.66
Today's Range
64.66 - 64.66
52wk Range
12.39 - 93.94
Shares Outstanding
94,441,892
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Denali Therapeutics Reports Full Year 2020 Financial Results and Business Highlights
February 25, 2021
From
GlobeNewswire News Releases
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target
February 25, 2021
Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised $123 million in Series B financing. The...
From
PR Newswire
Performance
YTD
-8.75%
-8.75%
1 Month
-7.27%
-7.27%
3 Month
+6.05%
+6.05%
6 Month
+102.70%
+102.70%
1 Year
+225.25%
+225.25%
More News
Read More
Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II)
February 12, 2021
From
GlobeNewswire News Releases
Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium™
February 05, 2021
From
GlobeNewswire News Releases
Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors
January 11, 2021
From
GlobeNewswire News Releases
Denali Therapeutics Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Broad Therapeutic Portfolio in Neurodegeneration
January 08, 2021
From
GlobeNewswire News Releases
10 Biggest Price Target Changes For Friday
February 26, 2021
Tags
Pre/Market Outlook
Benzinga
ETSY
From
Benzinga
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
February 19, 2021
Tags
STAA
BHC
DNLI
From
Benzinga
Lilly Strikes Licensing Deal With Rigel In Push Toward Neurological, Immunological Therapies
February 18, 2021
Tags
Benzinga
Penny Stocks
News
From
Benzinga
Denali's Enzyme Replacement Therapy Shows Encouraging Biomarker Effects In Early-Stage Hunter Syndrome Study
February 12, 2021
Tags
News
General
Benzinga
From
Benzinga
Cassava Stock Pops Again; Can It Take On Biogen In Alzheimer's Drugs?
February 16, 2021
From
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.